ClinicalTrials.gg
CompletedNCT05959954Updated Nov 20, 2026

Predicting Nociplastic Pain in Carpal Tunnel Syndrome Through Quantitative Sensory Testing

An observational study in Carpal Tunnel Syndrome and Chronic Pain, sponsored by Ahram Canadian University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Ahram Canadian University · Observational

How we know

Updated Nov 20, 2026Now CompletedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
229
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University — 5 open to participants now, 5 under way, none of them phase 3. Carpal Tunnel Syndrome · Ahram Canadian University.

Started
2023
with 9 others
Observational
7 of 10
5 open now
Registered
8th of 10
by date

Among the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, this one is one of 10 that started in 2023, is one of 7 observational ones, and was the 8th registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

5 of the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, or all of them as a file.
02

Study summary

This prospective observational study will examine whether sensory testing performed at study entry can help predict the pain pattern present 12 months later in adults with carpal tunnel syndrome (CTS). Adults with clinically and electrodiagnostically confirmed CTS will undergo baseline clinical assessment, questionnaires, nerve-conduction testing, pain-phenotype classification, and quantitative sensory testing (QST). The main QST measures will assess pressure-pain sensitivity at a site away from the affected hand, temporal summation of pain, and conditioned pain modulation. Participants will receive their usual clinical care; the study will not assign treatment. They will be reassessed at 6 and 12 months. The main outcome is whether the participant has a predominantly neuropathic CTS pain phenotype or a mixed neuropathic-nociplastic pain phenotype at 12 months. Follow-up phenotype assessors will not have access to baseline QST results. The study hypothesis is that baseline QST will provide prognostic information beyond standard clinical and electrodiagnostic characteristics.

03

Conditions studied

  • Carpal Tunnel Syndrome
  • Chronic Pain
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with clinical and electrodiagnostic evidence of carpal tunnel syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ages 18-60
  • Clinical diagnosis of CTS based on presence of parasthesias and/or pain in median nerve distribution, positive Phalen's test and/or Tinel's sign, and nocturnal symptoms
  • Electrodiagnostic evidence of median neuropathy at the wrist:

    1. Prolonged median motor distal latency >4.2 ms
    2. Prolonged median sensory latency >3.4 ms
  • Symptom duration between 6 months and 2 years (to exclude very early or very late stages)
  • Pain severity of ≥5 on 0-10 numerical rating scale
  • No evidence of thenar muscle atrophy on physical exam
  • No prior surgery or fracture of the affected wrist
  • No evidence of comorbid diabetes mellitus, cervical radiculopathy, polyneuropathy, or other neuromuscular disorders

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus, as a common cause of polyneuropathy, which can confound QST measures.
  • Cervical radiculopathy or other upper limb neuropathies, which can cause overlapping sensory symptoms and signs.
  • History of wrist fracture or surgery, which may cause structural abnormalities affecting nerve function.
  • Pregnancy, due to physiological changes that can affect nerve function.
  • Patients with severe thenar muscle atrophy, indicating long-standing severe median neuropathy.
  • Patients unable to provide or comply with study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
229 participants (actual)
Patient registry
No

Groups and cohorts

  • Carpal Tunnel Syndrome (CTS) Patients

    Adults with clinical and electrodiagnostic evidence of carpal tunnel syndrome.

    Diagnostic Test: Quantitative Sensory Testing (QST)

Interventions

  • Diagnostic testQuantitative Sensory Testing (QST)

    Quantitative Sensory Testing (QST) is a non-invasive diagnostic method used to assess sensory dysfunction. The test evaluates individual thresholds and pain responses to different types of mechanical, thermal, and electrical stimuli. For this study, QST will be used to gather baseline sensory data for patients with carpal tunnel syndrome. This information will then be used to predict the progression to nociplastic pain over a one-year follow-up period.

06

What researchers measure

Primary outcomes

  1. Progression to Nociplastic Pain

    Development of nociplastic pain in patients with carpal tunnel syndrome, as identified by a Kosek, by clinical criteria suggest by E., Clauw, D., Nijs, J., Baron, R., Gilron, I., Harris, R. E., ... \& Sterling, M. (2021). Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain, 162(11), 2629-2634.

    Time frame: 1 year from the start of the study

Secondary outcomes

  1. Change in Quantitative Sensory Testing (QST) Measures

    A significant change in QST measures could indicate the progression of sensory abnormalities in the participants. QST measures include thermal detection and pain thresholds, mechanical detection and pain thresholds, and vibration detection thresholds. Each of these thresholds is measured using specific testing equipment and protocols, and the exact scoring can vary based on the specific equipment and protocol used. In general, lower thresholds (i.e., the patient detects the stimulus at lower intensities) may indicate heightened sensitivity or hyperalgesia, while higher thresholds may indicate reduced sensitivity or hypoesthesia. Changes in these thresholds over time can indicate a worsening of sensory dysfunction.

    Time frame: Changes in QST at baseline and 1 year

  2. Boston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS)

    The 11-item BCTQ Symptom Severity Scale is scored from 1 to 5 per item; the scale score is the mean of completed items, with higher values indicating greater CTS symptom severity.

    Time frame: Baseline, 6 months and 12 months

  3. Boston Carpal Tunnel Questionnaire - Functional Status Scale (BCTQ-FSS)

    The 8-item BCTQ Functional Status Scale assesses difficulty with activities affected by CTS; higher mean scores indicate greater functional limitation

    Time frame: Baseline, 6 months, and 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Sep 2026, 37 months.

Of 40 non-industry observational studies under Carpal Tunnel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's 37 months is above that.

Counting every sponsor, half of 42 studies reached it within 18 months; a quarter within 11 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jul 2024 → Sep 2026 and completion Nov 2024 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2023
First posted
Jul 25, 2023
StartActual
Jul 26, 2023
Primary completionActual
Sep 8, 2026was Jul 2024
CompletionActual
Sep 8, 2026was Nov 2024
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 20, 2026
Sites
1 site added, 1 site removed
Show site
  • Outpatient clinic of faculty of physical therapy, Ahram Canadian University · Al Ḩayy Ath Thāmin, Egypt
Show 1 removed
  • Outpatient clinic of faculty of physical therapy, Ahram Canadian University · Al Ḩayy Ath Thāmin, Egypt
Nov 20, 2026
Start date
Jul 21, 2023→Jul 26, 2023 (actual)
Nov 20, 2026
Primary completion
Jul 21, 2024→Sep 8, 2026 (actual)
Nov 20, 2026
Study completion
Nov 30, 2024→Sep 8, 2026 (actual)
Nov 20, 2026
Enrollment
120 (estimated)→229 (actual)
Nov 20, 2026
Secondary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedBoston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS)Time frame: Baseline, 6 months and 12 months
  • AddedBoston Carpal Tunnel Questionnaire - Functional Status Scale (BCTQ-FSS)Time frame: Baseline, 6 months, and 12 months
  • Removedother outcomeChange in Hand FunctionTime frame: Change in hand function measures at baseline and 1 year.
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Outpatient clinic of faculty of physical therapy, Ahram Canadian University · Al Ḩayy Ath Thāmin, Egypt
    Show 1 removed
    • Outpatient clinic of faculty of physical therapy, Ahram Canadian University · Al Ḩayy Ath Thāmin, Egypt
    Start date Jul 21, 2023→Jul 26, 2023 (now actual)
    Primary completion Jul 21, 2024→Sep 8, 2026 (now actual)
    Study completion Nov 30, 2024→Sep 8, 2026 (now actual)
    Enrollment 120 (estimated)→229 (actual)
    Secondary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedBoston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS)Time frame: Baseline, 6 months and 12 months
    • AddedBoston Carpal Tunnel Questionnaire - Functional Status Scale (BCTQ-FSS)Time frame: Baseline, 6 months, and 12 months
    • Removedother outcomeChange in Hand FunctionTime frame: Change in hand function measures at baseline and 1 year.
    + 5 other changes: index terms, verification date, description, conditions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05959954
Lead sponsor
Ahram Canadian University
Responsible party
Mohamed Magdy ElMeligie (Lecturer of Physical Therapy and Director of Electromyography Lab, Ahram Canadian University) — Principal investigator
First posted
Jul 25, 2023
Start date
Jul 26, 2023
Primary completion
Sep 8, 2026
Completion
Sep 8, 2026
Last update
Nov 20, 2026

Study contacts

Amal Fawzy, Ph.d
study chair · Faculty of Physical Therapy, Ahram Canadian University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion